MedTrace Logo

A Study Evaluating the Safety and Efficacy of Tirofiban in Combination With Alteplase in Acute Ischemic Stroke

NCT05188417 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 266

Last updated 2023-02-23

No results posted yet for this study

Summary

The study is a prospective, multicenter, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of tirofiban in combination with intravenous thrombolytic therapy with alteplase in acute ischemic stroke

Conditions

  • Acute Ischemic Stroke

Interventions

DRUG

Tirofiban 0.05 MG/ML

intravenous injection of the drug according to different body weights and arms

DRUG

0.9% sodium chloride solution

intravenous injection of the drug according to different body weights and arms

Sponsors & Collaborators

  • GrandPharma (China) Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Zhipeng Wang, Ph.D, MD · GrandPharma (China) Co., Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-09
Primary Completion
2023-03-30
Completion
2023-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05188417 on ClinicalTrials.gov